Inotuzumab Ozogamicin Achieves 'Markedly Long' Antitumor Response in Indolent ... Cancer Network Inotuzumab ozogamicin was administered 1.8 mg/m 2 intravenously once every 28 days for a planned 4 to 8 cycles to patients whose indolent B-cell NHL was refractory to rituximab. Analysis was performed with a set of 28 patients with indolent NHL (24 ... |
